- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05955586
A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.
March 5, 2024 updated by: Spero Therapeutics
A Phase 1, Single-center, Open-label Study to Assess the Intrapulmonary Pharmacokinetics of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.
The primary purpose of this study is to evaluate the intrapulmonary PK, including epithelial lining fluid (ELF) and alveolar macrophages (AM) concentrations, of SPR719 compared to plasma concentrations of SPR719 (the active moiety in plasma of the prodrug SPR720) after oral administration of SPR720 1000 milligram (mg) capsules every 24 hours for 7 consecutive doses.
Study Overview
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Pulmonary Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Body mass index (BMI) ≥18.0 and ≤32.0 kilograms per meter square (kg/m^2) and weight between 55.0 and 100.0 kilograms (kg) (inclusive).
- Forced expiratory volume in 1 second (FEV1) of at least 80% of predicted value at screening visit.
- Have suitable venous access for blood sampling.
- Ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food or product containing any of these from 48 hours prior to study drug administration until discharge from the clinical research unit (CRU).
Key Exclusion Criteria:
- History of clinically significant acute illness or surgery within the previous 3 months prior to Screening Visit or Day -1.
- Known history of clinically significant hypersensitivity reaction or anaphylaxis to SPR720 or an aminobenzimidazole.
- Any condition possibly affecting drug absorption (e.g. previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas]).
- Participants who are unable to demonstrate the ability to swallow the dosage forms.
- Receipt of any other investigational medicinal product or participation in another investigational clinical study that included drug treatment within 30 days prior to Day 1 dose (based on the timing of the last Follow-up Visit in the previous study to Day 1 of the current study).
NOTE: Other inclusion and exclusion criteria as per protocol may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SPR720
Healthy participants will receive SPR720 1000 mg capsule, orally, for 7 days.
|
SPR720 1000 mg (250 mg*4 capsules) will be administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Concentration-time Curve from Time Zero to 24 Hours (AUC0-24) of SPR719 in plasma, ELF and AM
Time Frame: Predose on Day 6 and post-dose at multiple time points up to Day 8
|
Predose on Day 6 and post-dose at multiple time points up to Day 8
|
Maximum Observed Concentration (Cmax) of SPR719 in plasma, ELF and AM
Time Frame: Predose on Day 6 and post-dose at multiple time points up to Day 8
|
Predose on Day 6 and post-dose at multiple time points up to Day 8
|
Time to the Maximum Observed Concentration (Tmax) of SPR719 in plasma, ELF and AM
Time Frame: Predose on Day 6 and post-dose at multiple time points up to Day 8
|
Predose on Day 6 and post-dose at multiple time points up to Day 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: From first dose of study drug until the follow-up visit (up to 15 days)
|
From first dose of study drug until the follow-up visit (up to 15 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2023
Primary Completion (Actual)
February 9, 2024
Study Completion (Actual)
February 23, 2024
Study Registration Dates
First Submitted
July 13, 2023
First Submitted That Met QC Criteria
July 13, 2023
First Posted (Actual)
July 21, 2023
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- SPR720-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
AbbVieCompletedHealthy VolunteerUnited States
-
Taisho Pharmaceutical Co., Ltd.CompletedHealthy VolunteerJapan
Clinical Trials on SPR720
-
Spero TherapeuticsRecruitingNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)United States
-
Spero TherapeuticsSimbec ResearchCompletedHealthy VolunteersUnited Kingdom
-
Spero TherapeuticsTerminatedMycobacterium Avium Complex | Non-tuberculous Mycobacterium Pulmonary DiseaseUnited States
-
Spero TherapeuticsCompleted